1
|
Schafer DF and Sorrell MF: Hepatocellular
carcinoma. Lancet. 353:1253–1257. 1999. View Article : Google Scholar : PubMed/NCBI
|
2
|
Kerbel RS: Tumor angiogenesis: past,
present and the near future. Carcinogenesis. 21:505–515. 2000.
View Article : Google Scholar : PubMed/NCBI
|
3
|
Guo RP, Zhong C, Shi M, et al: Clinical
value of apoptosis and angiogenesis factors in estimating the
prognosis of hepatocellular carcinoma. J Cancer Res Clin Oncol.
132:547–555. 2006. View Article : Google Scholar : PubMed/NCBI
|
4
|
Iavarone M, Lampertico P, Iannuzzi F, et
al: Increased expression of vascular endothelial growth factor in
small hepatocellular carcinoma. J Viral Hepat. 14:133–139. 2007.
View Article : Google Scholar : PubMed/NCBI
|
5
|
Li CY, Shan S, Huang Q, et al: Initial
stages of tumor cell-induced angiogenesis: evaluation via skin
window chambers in rodent models. J Natl Cancer Inst. 92:143–147.
2000. View Article : Google Scholar
|
6
|
Bergers G and Benjamin LE: Tumorigenesis
and the angiogenic switch. Nat Rev Cancer. 3:401–410. 2003.
View Article : Google Scholar
|
7
|
Bergers G, Javaherian K, Lo KM, Folkman J
and Hanahan D: Effects of angiogenesis inhibitors on multistage
carcinogenesis in mice. Science. 284:808–812. 1999. View Article : Google Scholar : PubMed/NCBI
|
8
|
Brandvold KA, Neiman P and Ruddell A:
Angiogenesis is an early event in the generation of myc-induced
lymphomas. Oncogene. 19:2780–2785. 2000. View Article : Google Scholar : PubMed/NCBI
|
9
|
Yoshiji H, Kuriyama S, Yoshii J, et al:
Halting the interaction between vascular endothelial growth factor
and its receptors attenuates liver carcinogenesis in mice.
Hepatology. 39:1517–1524. 2004. View Article : Google Scholar : PubMed/NCBI
|
10
|
Frachon S, Gouysse G, Dumorti J, et al:
Endothelial cell marker expression in dysplastic lesions of the
liver: an immunohistochemical study. J Hepatol. 34:850–857. 2001.
View Article : Google Scholar : PubMed/NCBI
|
11
|
Kerbel RS: Tumor angiogenesis. N Engl J
Med. 358:2039–2049. 2008. View Article : Google Scholar : PubMed/NCBI
|
12
|
Wilhelm SM, Carter C, Tang L, et al: BAY
43-9006 exhibits broad spectrum oral antitumor activity and targets
the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in
tumor progression and angiogenesis. Cancer Res. 64:7099–7109. 2004.
View Article : Google Scholar : PubMed/NCBI
|
13
|
Llovet JM, Ricci S, Mazzaferro V, et al:
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med.
359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
|
14
|
Eskens FA and Verweij J: The clinical
toxicity profile of vascular endothelial growth factor (VEGF) and
vascular endothelial growth factor receptor (VEGFR) targeting
angiogenesis inhibitors: a review. Eur J Cancer. 42:3127–3139.
2006. View Article : Google Scholar
|
15
|
Verheul HM and Pinedo HM: Possible
molecular mechanisms involved in the toxicity of angiogenesis
inhibition. Nat Rev Cancer. 7:475–485. 2007. View Article : Google Scholar : PubMed/NCBI
|
16
|
Berenson A: A cancer drug shows promise,
at a price that many can’t pay. The New York Times.
A1:C22006.PubMed/NCBI
|
17
|
Yoshiji H, Kuriyama S, Noguchi R, et al:
Combination of vitamin K(2) and the angiotensin-converting enzyme
inhibitor, perindopril, attenuates the liver enzyme-altered
preneoplastic lesions in rats via angiogenesis suppression. J
Hepatol. 42:687–693. 2005. View Article : Google Scholar
|
18
|
Yoshiji H, Noguchi R, Yamazaki M, et al:
Combined treatment of vitamin K2 and angiotensin-converting enzyme
inhibitor ameliorates hepatic dysplastic nodule in a patient with
liver cirrhosis. World J Gastroenterol. 13:3259–3261. 2007.
|
19
|
Yoshiji H, Noguchi R, Toyohara M, et al:
Combination of vitamin K2 and angiotensin-converting enzyme
inhibitor ameliorates cumulative recurrence of hepatocellular
carcinoma. J Hepatol. 51:315–321. 2009. View Article : Google Scholar
|
20
|
Murukesh N, Dive C and Jayson GC:
Biomarkers of angiogenesis and their role in the development of
VEGF inhibitors. Br J Cancer. 102:8–18. 2010. View Article : Google Scholar : PubMed/NCBI
|
21
|
Kokudo N and Makuuchi M: Evidence-based
clinical practice guidelines for hepatocellular carcinoma in Japan:
the J-HCC guidelines. J Gastroenterol. 44:119–121. 2009. View Article : Google Scholar : PubMed/NCBI
|
22
|
Makuuchi M, Kokudo N, Arii S, et al:
Development of evidence-based clinical guidelines for the diagnosis
and treatment of hepatocellular carcinoma in Japan. Hepatol Res.
38:37–51. 2008. View Article : Google Scholar : PubMed/NCBI
|
23
|
Okita K: Management of hepatocellular
carcinoma in Japan. J Gastroenterol. 41:100–106. 2006. View Article : Google Scholar
|
24
|
Ferrara N: VEGF as a therapeutic target in
cancer. Oncology. 69(Suppl 3): 11–16. 2005. View Article : Google Scholar
|
25
|
Dowlati A, Gray R, Sandler AB, Schiller JH
and Johnson DH: Cell adhesion molecules, vascular endothelial
growth factor, and basic fibroblast growth factor in patients with
non-small cell lung cancer treated with chemotherapy with or
without bevacizumab – an Eastern Cooperative Oncology Group Study.
Clin Cancer Res. 14:1407–1412. 2008.
|
26
|
Nagaoka S, Yoshida T, Akiyoshi J, et al:
The ratio of serum placenta growth factor to soluble vascular
endothelial growth factor receptor-1 predicts the prognosis of
hepatocellular carcinoma. Oncol Rep. 23:1647–1654. 2010.
|
27
|
Yoshiji H, Kuriyama S, Yoshii J, et al:
Synergistic effect of basic fibroblast growth factor and vascular
endothelial growth factor in murine hepatocellular carcinoma.
Hepatology. 35:834–842. 2002. View Article : Google Scholar : PubMed/NCBI
|
28
|
Wierzbowska A, Robak T, Wrzesien-Kus A,
Krawczynska A, Lech-Maranda E and Urbanska-Rys H: Circulating VEGF
and its soluble receptors sVEGFR-1 and sVEGFR-2 in patients with
acute leukemia. Eur Cytokine Netw. 14:149–153. 2003.PubMed/NCBI
|
29
|
Corradini SG, Morini S, Liguori F, et al:
Differential vascular endothelial growth factor A protein
expression between small hepatocellular carcinoma and cirrhosis
correlates with serum vascular endothelial growth factor A and
alpha-fetoprotein. Liver Int. 29:103–112. 2009. View Article : Google Scholar
|
30
|
Deprimo SE, Bello CL, Smeraglia J, et al:
Circulating protein biomarkers of pharmacodynamic activity of
sunitinib in patients with metastatic renal cell carcinoma:
modulation of VEGF and VEGF-related proteins. J Transl Med.
5:322007. View Article : Google Scholar : PubMed/NCBI
|